The Beauty Health Company Statistics
Total Valuation
SKIN has a market cap or net worth of $178.50 million. The enterprise value is $340.09 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SKIN has 127.50 million shares outstanding. The number of shares has increased by 0.58% in one year.
| Current Share Class | 127.50M |
| Shares Outstanding | 127.50M |
| Shares Change (YoY) | +0.58% |
| Shares Change (QoQ) | -9.55% |
| Owned by Insiders (%) | 9.43% |
| Owned by Institutions (%) | 59.13% |
| Float | 82.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.58 |
| Forward PS | 0.59 |
| PB Ratio | 2.71 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 4.63 |
| P/OCF Ratio | 4.61 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 8.83 |
Financial Position
The company has a current ratio of 4.98, with a Debt / Equity ratio of 5.77.
| Current Ratio | 4.98 |
| Quick Ratio | 3.92 |
| Debt / Equity | 5.77 |
| Debt / EBITDA | 77.98 |
| Debt / FCF | 9.84 |
| Interest Coverage | -1.82 |
Financial Efficiency
Return on equity (ROE) is -18.73% and return on invested capital (ROIC) is -3.28%.
| Return on Equity (ROE) | -18.73% |
| Return on Assets (ROA) | -2.92% |
| Return on Invested Capital (ROIC) | -3.28% |
| Return on Capital Employed (ROCE) | -6.37% |
| Revenue Per Employee | $392,610 |
| Profits Per Employee | -$15,273 |
| Employee Count | 769 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 1.64 |
Taxes
| Income Tax | -1.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.17% in the last 52 weeks. The beta is 1.19, so SKIN's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -16.17% |
| 50-Day Moving Average | 1.80 |
| 200-Day Moving Average | 1.63 |
| Relative Strength Index (RSI) | 42.71 |
| Average Volume (20 Days) | 1,309,458 |
Short Selling Information
The latest short interest is 17.21 million, so 13.49% of the outstanding shares have been sold short.
| Short Interest | 17.21M |
| Short Previous Month | 17.38M |
| Short % of Shares Out | 13.49% |
| Short % of Float | 20.95% |
| Short Ratio (days to cover) | 18.61 |
Income Statement
In the last 12 months, SKIN had revenue of $301.92 million and -$11.75 million in losses. Loss per share was -$0.18.
| Revenue | 301.92M |
| Gross Profit | 195.67M |
| Operating Income | -28.12M |
| Pretax Income | -12.85M |
| Net Income | -11.75M |
| EBITDA | -1.57M |
| EBIT | -28.12M |
| Loss Per Share | -$0.18 |
Full Income StatementBalance Sheet
The company has $217.40 million in cash and $378.98 million in debt, giving a net cash position of -$161.58 million or -$1.27 per share.
| Cash & Cash Equivalents | 217.40M |
| Total Debt | 378.98M |
| Net Cash | -161.58M |
| Net Cash Per Share | -$1.27 |
| Equity (Book Value) | 65.66M |
| Book Value Per Share | 0.52 |
| Working Capital | 246.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $38.76 million and capital expenditures -$238,000, giving a free cash flow of $38.52 million.
| Operating Cash Flow | 38.76M |
| Capital Expenditures | -238,000 |
| Free Cash Flow | 38.52M |
| FCF Per Share | $0.30 |
Full Cash Flow StatementMargins
Gross margin is 64.81%, with operating and profit margins of -9.31% and -3.89%.
| Gross Margin | 64.81% |
| Operating Margin | -9.31% |
| Pretax Margin | -4.26% |
| Profit Margin | -3.89% |
| EBITDA Margin | -0.52% |
| EBIT Margin | -9.31% |
| FCF Margin | 12.76% |
Dividends & Yields
SKIN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.58% |
| Shareholder Yield | -0.58% |
| Earnings Yield | -6.58% |
| FCF Yield | 21.58% |
Analyst Forecast
The average price target for SKIN is $2.42, which is 72.86% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.42 |
| Price Target Difference | 72.86% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 2.45% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SKIN has an Altman Z-Score of -0.13 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.13 |
| Piotroski F-Score | 5 |
